Ron Lennox, D.Phil., M.B.A.

Ron Lennox's picture
Ron has invested broadly in the life science sector with an emphasis on biotechnology and molecular diagnostics. He is currently CEO of Monogram Orthopaedics, Inc., a spin-out from Mount Sinai School of Medicine where he also serves as an EIR. Monogram, which is based in Brooklyn, is developing the next generation of orthopaedic implants and surgical tools. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Protometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly). He was founding Chairman of Amicus Therapeutics (NASDAQ: FOLD, another Mount Sinai spin-out) and Chairman of Bikam Therapeutics where he managed its sale to Shire in 2014. He was founding CEO of two Yale start-ups, Protometrix, Inc. and CGI Pharmaceuticals, Inc (acquired by Gilead Sciences, Inc.). He was one of the three founding partners of CHL Medical Partners, and prior to that was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs. Ron graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania where he received his MBA.